Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia

    ... their unrelated donors who had pre-HCT blood samples and clinical and outcome data available at the Center for International Blood and Marrow Transplant Research. Patients underwent HCT between 1989 and 2007 in 84 centers and were ...

    Research Article last updated 03/03/2015 - 11:48am.

  2. Myelodysplastic syndromes in the United States: an update for clinicians

    ... most often in elderly white persons. MDS have significant clinical consequences, including cytopenias leading to infection, bleeding, ... morbidity and mortality in elderly patients. Recent research suggests MDS occurs more frequently than previously thought and may ...

    Research Article last updated 04/23/2014 - 11:46am.

  3. Akihide Yoshimi, MD, PhD

    ... Spliceosomal Mutations Original Research Center:  Memorial Sloan-Kettering Cancer Center ... this proposal are two-fold: (1) to determine the efficacy of clinical-grade novel spliceosome inhibitors in splicing factor-mutant versus ...

    Grant Recipient last updated 06/08/2017 - 10:42am.

  4. Coleman Lindsley, MD, PhD

    ... myelodysplastic syndromes Original Research Center:  Dana Farber Cancer Institute ... inherited changes in telomerase genes that are of unknown clinical significance. Our results suggest that inherited variability in ...

    Grant Recipient last updated 06/05/2017 - 11:04am.

  5. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

    ... Anemia remains the most challenging clinical manifestation to treat in patients with lower-risk ... chromosomal abnormality. Lenalidomide also has meaningful clinical activity in lower-risk patients without deletion 5q. The experience ... in MDS is a modern example of reciprocal translational research, in which bench work led to an approved drug for patients, and ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. What MDS Patients Should Know About Clinical Trials

    ... Do you find that some patients don’t understand what clinical trials are? There’s a wide range of patient knowledge and ... ask me about them because they want to be part of the latest research and latest opportunities to try new drugs or drug combinations for ...

    Interview last updated 11/13/2015 - 11:12am.

  7. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

    ... toxicity and relapse rates is another area of active research. SUMMARY: Sequential switching to the alternative HMA, clinical trials of novel targeted therapies, azacitidine-based combination ...

    Research Article last updated 01/08/2014 - 9:15am.

  8. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.

    ... conditions and, to some extent, appear to define distinct clinical phenotypes in MDS. The high frequency of mutations in different ... targets of the spliceosome mutations is an active area of research. Emerging data from the study of the MDS transcriptome suggests that ...

    Research Article last updated 10/22/2013 - 3:41pm.

  9. Overview of myelodysplastic syndromes

    ... by diagnostic entities of world renown as well as by other research groups and individuals to establish a reliable prognostic system. ... subgroups and the role of molecular markers in predicting clinical evolution. Bone Marrow Diseases:  ...

    Research Article last updated 11/05/2012 - 9:53am.

  10. Genetics of myelodysplastic syndromes: new insights

    ... contribute to disease pathogenesis is an active area of research, with a current focus on which downstream target genes may be ... are sufficiently robust to be incorporated into routine clinical practice at this time. Additional studies will be required to ...

    Research Article last updated 01/09/2012 - 2:04pm.